NASDAQ
26.06.25 | 21:41
0,998 US-Dollar
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 01.05. | Shattuck Labs GAAP EPS of -$0.27 beats by $0.01 | 1 | Seeking Alpha | ||
| 01.05. | Shattuck Labs, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 01.05. | Shattuck Labs, Inc.: Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights | 101 | GlobeNewswire (Europe) | - Company advances SL-325 program with an IND filing expected in the third quarter of 2025 - - Cash balance of approximately $60.9 million as of March 31, 2025, expected to fund operations into 2027... ► Artikel lesen | |
| 01.05. | Shattuck Labs, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| SHATTUCK LABS Aktie jetzt für 0€ handeln | |||||
| 30.04. | Shattuck Labs, Inc. - 10-K/A, Annual Report | 2 | SEC Filings | ||
| 02.04. | Shattuck Labs GAAP EPS of -$0.37 | 1 | Seeking Alpha | ||
| 28.03. | H.C. Wainwright holds Shattuck Labs stock at Neutral | 2 | Investing.com | ||
| 27.03. | Shattuck Labs, Inc Loss At -$18.68 Mln In Q4 | 1 | RTTNews | ||
| 27.03. | Shattuck Labs, Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 27.03. | Shattuck Labs, Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 27.03. | Shattuck Labs, Inc.: Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights | 374 | GlobeNewswire (Europe) | - Presented preclinical non-human primate (NHP) data at the 20th Congress of European Crohn's and Colitis Organization in Inflammatory Bowel Diseases 2025 (ECCO) for SL-325, a potentially first-in-class... ► Artikel lesen | |
| 27.03. | Shattuck Labs, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.03. | Leerink initiates Shattuck Labs stock with Outperform, $4 target | 2 | Investing.com | ||
| 20.02. | Shattuck Labs berichtet über positive präklinische Daten für SL-325 | 2 | Investing.com Deutsch | ||
| 13.02. | Shattuck Labs, Inc.: Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn's and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025 | 2 | GlobeNewswire (USA) | ||
| 04.02. | Shattuck Labs, Inc.: Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn's and Colitis Congress | 2 | GlobeNewswire (USA) | ||
| 02.01. | Shattuck Labs gears up for DR3 antagonist trials in 2025 | 2 | Investing.com | ||
| 02.01. | Shattuck Labs, Inc.: Shattuck Labs Provides Corporate Update and Highlights Upcoming Key Milestones in 2025 | 137 | GlobeNewswire (Europe) | AUSTIN, TX and DURHAM, NC, Jan. 02, 2025 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a biotechnology company pioneering the development of novel therapeutics targeting tumor... ► Artikel lesen | |
| 01.10.24 | Pre-market Movers: Shattuck Labs, SITE Centers, IGM Biosciences, ATIF Holdings, Arqit Quantum | 895 | AFX News | OTTAWA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 07.45 A.M. ET).In the Green SITE Centers Corp. (SITC) is up over 53% at $18.12.
ATIF... ► Artikel lesen | |
| 01.10.24 | Shattuck Labs, Inc.: Shattuck Labs Provides Company Update and Announces SL-325, a First-In-Class Death Receptor 3 (DR3) Antagonist Targeting the TL1A/DR3 Signaling Pathway | 121 | GlobeNewswire (Europe) | - Interim clinical data for SL-172154 in combination with azacitidine in TP53 mutant (TP53m) acute myeloid leukemia (AML) and higher-risk myelodysplastic syndromes (HR-MDS) showed only modest improvement... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 41,230 | +2,74 % | Minimale Kursveränderung bei Qiagen NV-Aktie (40,55 €) | Am Aktienmarkt ist der Anteilsschein von Qiagen NV gegenwärtig unauffällig. Das Wertpapier kostete zuletzt 40,55 Euro. Der heutige Börsentag brachte bislang wenig Kursbewegung bei der Aktie von Qiagen... ► Artikel lesen | |
| VOR BIOPHARMA | 0,890 | 0,00 % | Pre-market Movers: Vor Biopharma, Worthington Steel, Surf Air Mobility, Nano Labs, Protagenic Therapeutics | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 07.30 A.M. ET).In the Green Vor Biopharma Inc. (VOR) is up over 109% at $1.16.
Worthington... ► Artikel lesen | |
| TARSUS PHARMACEUTICALS | 40,330 | +0,40 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports First Quarter 2025 Financial Results and Recent Business Achievements | Generated $78.3 million in net product sales of XDEMVY®, an increase of 217% year over year and 18% over Q4 2024, and dispensed approximately 72,000 bottles to patients Strengthened financial position... ► Artikel lesen | |
| SPRINGWORKS THERAPEUTICS | 46,990 | +0,04 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Receives Positive CHMP Opinion for Nirogacestat for the Treatment of Adults with Desmoid Tumors | - If approved, nirogacestat will be the first and only therapy with marketing authorization in the EU for the treatment of desmoid tumors -
- Decision from European Commission expected in the third... ► Artikel lesen | |
| VERVE THERAPEUTICS | 11,255 | 0,00 % | BMO Capital stuft Verve Therapeutics nach Eli Lilly-Übernahme herab | ||
| EVOTEC | 7,196 | +0,50 % | Evotec-Aktie: Kurs legt zu (6,734 €) | Am deutschen Aktienmarkt notiert die Evotec-Aktie derzeit etwas fester. Zuletzt zahlten Investoren für das Wertpapier 6,73 Euro. Der Anteilsschein von Evotec verzeichnet gegenwärtig einen Preisanstieg... ► Artikel lesen | |
| BIONTECH | 90,80 | +0,17 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,410 | 0,00 % | Recursion Pharmaceuticals: Recursion Reports First Quarter 2025 Financial Results and Provides Business Update | Pipeline: Delivered on our commitment to a more focused R&D strategy by advancing a streamlined portfolio of 5+ clinical and preclinical programs in oncology and rare disease, while deprioritizing... ► Artikel lesen | |
| ADMA BIOLOGICS | 18,380 | +4,43 % | ADMA vs Takeda: Which Plasma Therapy Stock Is the Better Buy Today? | ||
| KYMERA THERAPEUTICS | 45,720 | 0,00 % | Gilead Sciences Partners Kymera Therapeutics To Develop Novel Oral Molecular Glue CDK2 Degraders | FOSTER CITY (dpa-AFX) - Gilead Sciences, Inc. (GILD) and Kymera Therapeutics, Inc. (KYMR) announced Wednesday that they have entered into an exclusive option and license agreement to accelerate... ► Artikel lesen | |
| ITEOS THERAPEUTICS | 10,020 | -0,20 % | iTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down Operations | - Board of Directors intends to cease operations - Company to focus efforts on selecting best path to deliver near-term value to shareholders - Exploring potential asset sales including EOS-984, EOS-215... ► Artikel lesen | |
| PHATHOM PHARMACEUTICALS | 9,550 | 0,00 % | Phathom Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | FLORHAM PARK, N.J., June 23, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal... ► Artikel lesen | |
| KEROS THERAPEUTICS | 13,510 | -1,31 % | Keros Therapeutics, Inc.: Keros Announces Return of $375 Million in Excess Capital to Stockholders | LEXINGTON, Mass., June 09, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. ("Keros" or the "Company") (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 13,050 | 0,00 % | Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies | - New open label data in Becker demonstrated sustained disease stabilization up to three years, reinforcing prior clinical findings -- Ongoing pivotal trial and FDA Type C meeting provide... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 21,310 | 0,00 % | H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target |
SHATTUCK LABS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 0,998 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SHATTUCK LABS INC finden Sie auf Wallstreet Online.